Anti-CD19 CAR-T cell product

2025: Application Initiation

Russia For the first time, a patient was treated using a domestic individual biomedical cell product anti-CD19. CAR-T The therapy was received by a man diagnosed with diffuse B-large cell lymphoma - one of the most common and aggressive forms of this disease. The cell product was manufactured under the conditions of the Scientific and Production Complex of the National Medical Research Center of Radiology Ministry of Health Russia in accordance with GMP standards. This was reported MNII named after P.A. Herzen in the branch of the National Medical Research Center of Radiology of the Ministry of Health of Russia on October 2, 2025.

The patient developed the disease rapidly. Two months after the first line of therapy, early progression of the disease occurred. Almost all bones of the skeleton were affected, except for the sternum. The central nervous system was also affected by the tumor process. On the second line of treatment, only a partial response was achieved. The disease continued to progress despite therapy.

𝓲

Фото: nmicr.ru

Bone marrow transplantation was not possible in this case. Severe concomitant cardiology prevented the patient from using this method. The partial antitumor effect on the second-line therapy also limited the options. The only option for effective treatment remained innovative CAR-T therapy. The method involves genetic modification of the patient's own immune cells.

The manufacture of the drug took nine days. After production, the cell product was administered to the patient. Senior Researcher of the Group of High-Dose Chemotherapy and Bone Marrow Transplantation, P.A. Herzen, Candidate of Medical Sciences Mobil Akhmedov spoke about the patient's condition. According to him, an important step has been taken not only in the treatment of a specific patient, but also in the development of CAR-T therapy practice in the country. The patient underwent the administration of the drug well. The man feels cheerful, communicates and smiles. Prevention of possible immunological and infectious complications is carried out. A follow-up PET study will be conducted in a month to assess treatment outcomes.^[1]

Notes